Recro Pharma, Inc.: directors' dealings · United States · SEC (Form 4)

About Recro Pharma, Inc.

Recro Pharma, Inc. (historical ticker REPH) was a U.S.-based pharmaceutical services company incorporated in Pennsylvania on November 15, 2007. Over time, the company transitioned from an early-stage specialty pharma profile into a contract development and manufacturing organization (CDMO), and it formally changed its name to Societal CDMO in March 2022. For investors in France, Belgium, and Switzerland, the key point is that this is a United States issuer that was listed on NASDAQ, with its identity increasingly tied to pharmaceutical outsourcing rather than standalone drug commercialization. The company’s core business focused on drug formulation, development, manufacturing, and packaging, with a primary emphasis on small molecules and complex dosage forms. Societal CDMO described itself as a bi-coastal CDMO with capabilities spanning pre-Investigational New Drug (pre-IND) development through commercial manufacturing and packaging. That end-to-end model allowed it to support clients across early development, clinical supply, regulatory support, scale-up, and commercial production. It also highlighted experience with DEA-controlled substances and modified-release dosage forms, which is relevant in a CDMO market where technical differentiation and compliance capabilities often determine client wins. Geographically, the business operated from facilities in Gainesville, Georgia, and San Diego, California, giving it a U.S. East Coast / West Coast footprint. This two-site structure helped the company serve domestic and international pharmaceutical customers while broadening its manufacturing and development capacity. In competitive terms, Recro/Societal operated in a crowded and highly regulated CDMO market, competing with specialized peers such as CoreRx, Adare Pharma Solutions, Avara Pharmaceutical Services, Quotient Sciences, and with CDMO divisions embedded in larger healthcare and life-science groups. Relative scale was a challenge, so the company’s investment case depended on niche capabilities, customer diversification, operational execution, and the ability to convert technical expertise into recurring manufacturing revenue. Recent corporate developments were significant. In February 2024, Societal CDMO announced a definitive agreement to be acquired by CoreRx in an all-cash transaction at $1.10 per share, with the board unanimously approving the deal and recommending that shareholders tender their shares. Management described the transaction as a way to create a stronger CDMO platform with broader formulation development, clinical services, commercial manufacturing, and packaging capabilities. For anyone analyzing SEC Form 4 insider transactions or legacy REPH filings, the most important context is that this became a change-of-control situation, reflecting broader consolidation pressures in the U.S. CDMO sector.